finance
How 2026’s Gene‑Editing and Immunotherapy Breakthroughs Could Reshape Your Investment Portfolio
How 2026’s Gene-Editing and Immunotherapy Breakthroughs Could Reshape Your Investment Portfolio Why Gene-Editing and Immunotherapy Matter to Investors In 2026, the convergence of CRISPR-based gene editing and next-generation immunotherapies is not just a medical revolution; it is a seismic shift in the investment landscape. Companies that pioneered early gene-therapy